Skip to Main Content

Author Details

Eva Corey
University of Washington School of Medicine
1996
187
51
PMIDPaper TitleJournal TitlePublished Year
36993422GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior.bioRxiv2024
37796107Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.Prostate2024
37850574Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.J Pathol2024
36374194OncoLoop: A Network-Based Precision Cancer Medicine Framework.Cancer Discov2023
37636316Co-evolution of <i>AR</i> gene copy number and structural complexity in endocrine therapy resistant prostate cancer.NAR Cancer2023
37798372ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.Br J Cancer2023
37956856Targeting the αVβ3/NgR2 pathway in neuroendocrine prostate cancer.Matrix Biol2023
38049604Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment.Nat Cell Biol2023
37577653Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.bioRxiv2023
37823778Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.Cancer Res Commun2023
37725435Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.J Clin Invest2023
37352376Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.Cancer Res2023
37347559Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth.J Clin Invest2023
37333335A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.bioRxiv2023
37065756ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.Front Endocrinol (Lausanne)2023
36650259The future of patient-derived xenografts in prostate cancer research.Nat Rev Urol2023
36877164LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.Cancer Res2023
36399432Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.Cancer Discov2023
36865297Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients.medRxiv2023
36596844Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.Oncogene2023
36821396Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.JCI Insight2023
36112348Subtype and Site Specific-Induced Metabolic Vulnerabilities in Prostate Cancer.Mol Cancer Res2023
34355530Magneto-Endosomalytic Therapy for Cancer.Adv Healthc Mater2022
35406510Proteomic and Transcriptomic Profiling Reveals Mitochondrial Oxidative Phosphorylation as Therapeutic Vulnerability in Androgen Receptor Pathway Active Prostate Tumors.Cancers (Basel)2022
35468964HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer.Nat Genet2022
35603787Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome.JCI Insight2022
35695870Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Clin Cancer Res2022
35562350MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.Nat Commun2022
35552660Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2022
36561929IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis.Cancer Res Commun2022
36142567Oxidation of <i>p</i>-[<sup>125</sup>I]Iodobenzoic Acid and <i>p</i>-[<sup>211</sup>At]Astatobenzoic Acid Derivatives and Evaluation In Vivo.Int J Mol Sci2022
35963852Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer.Nat Commun2022
36159187Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes.Commun Med (Lond)2022
36344556The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancer.Sci Rep2022
35188070Small extracellular vesicle-mediated <i>ITGB6</i> siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells.Cancer Biol Ther2022
35121110Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer.Mol Ther2022
34907080Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis.Clin Cancer Res2022
33481853Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression.PLoS One2021
33483372Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer.Cancer Res2021
33785741Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.Nat Commun2021
33537376Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer.Data Brief2021
33724955Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.JCI Insight2021
33556543Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy.Cancer Lett2021
33633154A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture.Sci Rep2021
33916325Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling.Cancers (Basel)2021
34857732Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression.Nat Commun2021
34877933Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.JCI Insight2021
34548906Altered glucuronidation deregulates androgen dependent response profiles and signifies castration resistance in prostate cancer.Oncotarget2021
34431104Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer.J Pathol2021
34128479Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.J Clin Invest2021
  • 1 - 50 of 187

Recommended Authors

Natalie Kurganovs
Australian Prostate Cancer Research Centre Epworth
Career Start Year 2015
Number of shared co-authors 3
Richard J Rebello
University of Melbourne
Career Start Year 2015
Number of shared co-authors 8
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 7
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 37
Brian W Simons
Center for Comparative Medicine, Baylor College of Medicine
Career Start Year 2008
Number of shared co-authors 20
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 11
Channing J Paller
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 25
Gerhardt Attard
The Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 48
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 33
Luke A Selth
Adelaide Medical School, University of Adelaide
Career Start Year 2002
Number of shared co-authors 30
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 23
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 33
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 15
Kim N Chi
University of British Columbia
Career Start Year 2000
Number of shared co-authors 60
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2000
Number of shared co-authors 67
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 45
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 14
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 35
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Career Start Year 1995
Number of shared co-authors 62
Michael A Carducci
Johns Hopkins School of Medicine
Career Start Year 1995
Number of shared co-authors 39
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 33
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Career Start Year 1993
Number of shared co-authors 61
Edwin M Posadas
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 48
Marshall Scott Lucia
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 6
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 55
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 14
Adrie van Bokhoven
University of Colorado Anschutz Medical Campus
Career Start Year 1988
Number of shared co-authors 2
Anders Bjartell
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 53
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 70
Howard I Scher
Memorial Sloan Kettering Cancer Center
Career Start Year 1973
Number of shared co-authors 56

Collaborators

Robert L Vessella
University of Washington
Co-authored papers 71
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 65
Colm Morrissey
Co-authored papers 52
Ilsa Coleman
Fred Hutchinson Cancer Center
Co-authored papers 49
Lawrence D True
University of Washington School of Medicine
Co-authored papers 26
Elahe A Mostaghel
University of Washington
Co-authored papers 15
Michael C Haffner
Fred Hutchinson Cancer Center
Co-authored papers 15
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 14
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers 13
Stephen R Plymate
University of Washington
Co-authored papers 11
Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
Co-authored papers 9
Matthew L Freedman
Dana-Farber Cancer Institute
Co-authored papers 7
Alexandra Corella
Fred Hutchinson Cancer Research Center
Co-authored papers 6
Mark M Pomerantz
Dana-Farber Cancer Institute
Co-authored papers 6
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 6
Yuzhuo Wang
University of British Columbia
Co-authored papers 5
Sylvan C Baca
Co-authored papers 5
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 5
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 5
Shuai Gao
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 4
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 4
Gail P Risbridger
Biomedicine Discovery Institute, Monash University
Co-authored papers 4
Edward O'Connor
Dana-Farber Cancer Institute
Co-authored papers 4
Connor Bell
Dana-Farber Cancer Institute
Co-authored papers 4
Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 4
Changmeng Cai
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 4
Jeffrey A Kiefer
Co-authored papers 3
Adam G Sowalsky
National Cancer Institute
Co-authored papers 3
Wanting Han
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 3
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 3
Release 1.2